News & Videos - VIRIDIAN THERAPEUTICS INC.

- Topline data from proof-of-concept study of VRDN-001 in patients with chronic thyroid eye disease (TED) are expected in June/July 2023 - - Selection of lead subcutaneous (SC) program in TED planned for year-end 2023 - - Company adds multiple senior executives to its leadership team, including its first Chief Commercial Officer, as part of its ongoing growth - - Conference call today at 4:30pm ET - WALTHAM, Mass., May 09, 2023 (GLOBE NEWSWIRE) -- Viridian Therapeutics, Inc. (NASDAQ: VRDN), a...

- Partnership to support one of the Company’s preclinical programs outside of thyroid eye disease (TED) - WALTHAM, Mass., May 08, 2023 (GLOBE NEWSWIRE) -- Viridian Therapeutics, Inc. (NASDAQ: VRDN), a biotechnology company focused on discovering and developing potential best-in-class medicines for serious and rare diseases, today announced a new partnership with Enable Injections, a company developing and manufacturing the enFuse ® innovative wearable drug delivery system for volumes of up to...

WALTHAM, Mass., May 04, 2023 (GLOBE NEWSWIRE) -- Viridian Therapeutics, Inc. (Nasdaq: VRDN) (the “Company” or “Viridian”), a biopharmaceutical company focused on discovering and developing potential best-in-class medicines for serious and rare diseases, today announced that a majority of the independent directors serving on the Compensation Committee of the Company’s Board of Directors approved the grant of non-qualified stock options to purchase an aggregate of 96,000 shares of the...

WALTHAM, Mass., May 02, 2023 (GLOBE NEWSWIRE) -- Viridian Therapeutics, Inc. (NASDAQ: VRDN), a biopharmaceutical company focused on discovering and developing potential best-in-class medicines for serious and rare diseases, today announced it will host a webcast and conference call on Tuesday, May 9, 2023 at 4:30 p.m. ET to discuss its first quarter 2023 financial results and provide a corporate update. The webcast can be accessed under “Events and Presentations” on the Investors section of...

- Presentations to cover updated clinical and preclinical data on pipeline candidates in Company’s thyroid eye disease program - - Platform presentation to feature data from ongoing Phase 1/2 trial of VRDN-001 - - Poster presentations to feature new clinical and preclinical research on VRDN-002 and VRDN-003 - WALTHAM, Mass., April 20, 2023 (GLOBE NEWSWIRE) -- Viridian Therapeutics, Inc. (NASDAQ: VRDN), a biopharmaceutical company focused on discovering and developing potential best-in-class...

- Presentations to cover updated clinical and preclinical data on pipeline candidates in Company’s thyroid eye disease program - - Platform presentation to feature data from ongoing Phase 1/2 trial of VRDN-001 - - Poster presentations to feature new clinical and preclinical research on VRDN-002 and VRDN-003 - WALTHAM, Mass., April 20, 2023 (GLOBE NEWSWIRE) -- Viridian Therapeutics, Inc. (NASDAQ: VRDN), a biopharmaceutical company focused on discovering and developing potential best-in-class...

WALTHAM, Mass., April 12, 2023 (GLOBE NEWSWIRE) -- Viridian Therapeutics, Inc. (NASDAQ: VRDN), a biopharmaceutical company focused on discovering and developing potential best-in-class medicines for serious and rare diseases, today announced the appointment of Tony Casciano to the role of Chief Commercial Officer (CCO). The Company also announced that Chief Operating Officer (COO) Carrie Melvin is no longer with the organization. Mr. Casciano, who most recently served as Chief Executive Officer...

WALTHAM, Mass., April 04, 2023 (GLOBE NEWSWIRE) -- Viridian Therapeutics, Inc. (Nasdaq: VRDN) (the “Company” or “Viridian”), a biopharmaceutical company focused on discovering and developing potential best-in-class medicines for serious and rare diseases, today announced that a majority of the independent directors serving on the Company’s Board of Directors or the Compensation Committee thereof, as applicable, approved the grant of non-qualified stock options to purchase an aggregate...

- Positive data reported from ongoing Phase 1/2 trial evaluating low-dose VRDN-001 in patients with thyroid eye disease (TED) - - First patient enrolled in ‘THRIVE’ Phase 3 trial in patients with active TED, with results expected in mid-2024 - - Initial results from the proof-of-concept study of VRDN-001 in patients with chronic TED are expected in the second quarter of 2023 - - Selection of lead subcutaneous program in TED planned for year-end 2023 - WALTHAM, Mass., March 08, 2023 (GLOBE...

- Data from ongoing Phase 1/2 trial of VRDN-001 to be presented during oral platform session - - Additional poster presentations to cover trial design, early-stage clinical and mechanistic data on pipeline candidates in Company’s thyroid eye disease program - WALTHAM, Mass., March 07, 2023 (GLOBE NEWSWIRE) -- Viridian Therapeutics, Inc. (NASDAQ: VRDN), a biopharmaceutical company focused on discovering and developing potential best-in-class medicines for serious and rare diseases, today...

WALTHAM, Mass., March 03, 2023 (GLOBE NEWSWIRE) -- Viridian Therapeutics, Inc. (Nasdaq: VRDN) (the “Company” or “Viridian”), a biopharmaceutical company focused on discovering and developing potential best-in-class medicines for serious and rare diseases, today announced that a majority of the independent directors serving on the Compensation Committee of the Company’s Board of Directors approved the grant of non-qualified stock options to purchase an aggregate of 337,000 shares of the...

WALTHAM, Mass., March 01, 2023 (GLOBE NEWSWIRE) -- Viridian Therapeutics, Inc. (NASDAQ: VRDN), a biopharmaceutical company focused on discovering and developing potential best-in-class medicines for serious and rare diseases, today announced it will host a webcast and conference call on Wednesday, March 8, 2023 at 8:00 a.m. ET to discuss its fourth quarter and full year 2022 financial results. The webcast can be accessed under “Events and Presentations” on the Investors section of the...

WALTHAM, Mass., Feb. 28, 2023 (GLOBE NEWSWIRE) -- Viridian Therapeutics, Inc. (NASDAQ: VRDN), a biopharmaceutical company focused on discovering and developing potential best-in-class medicines for serious and rare diseases, today announced that senior management will present at Cowen’s 43 rd Annual Health Care Conference on Wednesday, March 8, 2023 at 1:30 p.m. ET in Boston, MA. A live webcast of the presentation can be accessed under “Events and Presentations” on the Investors section of...

WALTHAM, Mass., Feb. 07, 2023 (GLOBE NEWSWIRE) -- Viridian Therapeutics, Inc. (NASDAQ: VRDN), a biopharmaceutical company focused on discovering and developing potential best-in-class medicines for serious and rare diseases, today announced that senior management will participate in a fireside chat at the SVB Securities Virtual Global Biopharma Conference on Wednesday, February 15, 2023 at 1:00 p.m. ET. A live webcast of the fireside chat can be accessed under “Events and Presentations” on...

WALTHAM, Mass., Feb. 06, 2023 (GLOBE NEWSWIRE) -- Viridian Therapeutics, Inc. (NASDAQ: VRDN), a biopharmaceutical company focused on discovering and developing potential best-in-class medicines for serious and rare diseases, today announced that the Company has appointed Scott Myers as President and Chief Executive Officer, and a member of the Board of Directors, effective today February 6, 2023. Mr. Myers has more than 30 years of biopharmaceutical and medical technology experience, and has...

WALTHAM, Mass., Feb. 02, 2023 (GLOBE NEWSWIRE) -- Viridian Therapeutics, Inc. (Nasdaq: VRDN) (the “Company” or “Viridian”), a biopharmaceutical company focused on discovering and developing potential best-in-class medicines for serious and rare diseases, today announced that a majority of the independent directors serving on the Compensation Committee of the Company’s Board of Directors approved the grant of non-qualified stock options to purchase an aggregate of 332,000 shares of the...

- Significant and rapid improvement in both signs and symptoms of TED after two infusions of 3 mg/kg, generally consistent with prior 10 and 20 mg/kg results – - Among 3 mg/kg VRDN-001 treated patients, 67% were proptosis responders, 56% were overall responders, 67% achieved a Clinical Activity Score (CAS) of 0 or 1, and 20% had complete resolution of their diplopia – - Across all 21 VRDN-001 treated patients to date, 71% were proptosis responders, 67% were overall responders, 62% achieved a...

WALTHAM, Mass., Jan. 05, 2023 (GLOBE NEWSWIRE) -- Viridian Therapeutics, Inc. (Nasdaq: VRDN) (the “Company” or “Viridian”), a biopharmaceutical company focused on discovering and developing potential best-in-class medicines for serious and rare diseases, today announced that a majority of the independent directors serving on the Compensation Committee of the Company’s Board of Directors approved the grant of non-qualified stock options to an employee to purchase up to 35,000 shares of...

WALTHAM, Mass., Jan. 03, 2023 (GLOBE NEWSWIRE) -- Viridian Therapeutics, Inc. (NASDAQ: VRDN), a biopharmaceutical company focused on discovering and developing potential best-in-class medicines for serious and rare diseases, today announced that its President and Chief Executive Officer, Jonathan Violin, Ph.D., will present an overview of the company along with its upcoming corporate priorities at the 41st Annual J.P. Morgan Healthcare Conference on Monday, January 9, 2023 at 2:15 p.m. PST /...

- The global THRIVE Phase 3 trial will be conducted in approximately 50 centers across North America and Europe - - Topline results for the THRIVE Phase 3 trial are expected in the middle of 2024 – WALTHAM, Mass., Dec. 21, 2022 (GLOBE NEWSWIRE) -- Viridian Therapeutics, Inc. (NASDAQ: VRDN), a biopharmaceutical company focused on discovering and developing potential best-in-class medicines for serious and rare diseases, today announced that the first patient has been enrolled in its THRIVE...